echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Lung Cancer: The efficacy of brigatinib in the treatment of previously treated ALK+ metastatic non-small cell lung cancer patients: a real-world study

    Lung Cancer: The efficacy of brigatinib in the treatment of previously treated ALK+ metastatic non-small cell lung cancer patients: a real-world study

    • Last Update: 2021-07-31
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Non-small cell lung cancer ( NSCLC ) accounts for approximately 85% of lung cancer diagnoses
    .


    Anaplastic lymphoma kinase (ALK) gene rearrangement occurs in approximately 3.


    Non-small cell lung cancer ( NSCLC ) accounts for approximately 85% of lung cancer diagnoses


    Crizotinib is the first generation ALK tyrosine kinase inhibitor (TKI) and the first drug specifically approved for this patient.


    UVEA-Brig is a multi-center retrospective study conducted abroad to evaluate the efficacy of brigatinib after the progress of ALK + NSCLC patients with ALK inhibitors


    A total of 104 patients , (male: 43%; median age: 53[29 80] years; ECOG score 0/1/2/3: 41/ 41/10/5%; brain/central nervous system metastasis: 63 %) .
    The median follow-up was 16.
    5 months .
    34 patients received first-line ALK-TKI treatment, and most of them received first-line chemotherapy .
    Before using 81 patients received at least Bucharest erlotinib treatment system 2 in 69 patients (85%) received second-line ALK TKI (gefitinib g oxadiazol 57 is embodiment , the plug Swiss imatinib 11 cases , workers pull gefitinib 1 case ) .
    Of the 104 patients, 74 (71%) received radiotherapy .
     

    A total of 104 patients , (male: 43%; median age: 53[29 80] years; ECOG score 0/1/2/3: 41/ 41/10/5%; brain/central nervous system metastasis: 63 %) .


    The median follow-up was 16.
    5 months .
    34 patients received first-line ALK-TKI treatment, and most of them received first-line chemotherapy .
    Before using 81 patients received at least Bucharest erlotinib treatment system 2 in 69 patients (85%) received second-line ALK TKI (gefitinib g oxadiazol 57 is embodiment , the plug Swiss imatinib 11 cases , workers pull gefitinib 1 case ) .
    Of the 104 patients, 74 (71%) received radiotherapy .


    Previous treatment drugs

               Past treatment drugs Past treatment drugs

    The total median duration of brigatinib treatment was 16.


    5 months (95% CI: 12.
    9 to 18.
    5); at the time of data analysis , 27 patients were still receiving brigatinib treatment


    The total median duration of brigatinib treatment was 16.


              Efficacy evaluation

              Efficacy assessment Efficacy assessment

                 PFS and OS

                 PFS and OS              PFS and OS

    57 out of 65 patients with brain/central nervous system metastases can be evaluated
    .


    Among 57 patients, 23 patients (40.


    57 out of 65 patients with brain/central nervous system metastases can be evaluated


    At the time of analysis, 77 patients had discontinued brigatinib treatment, with a median discontinuation time of 8.


    In summary, after ALK + NSCLC patients use ALK inhibitors, taking brigatinib is still effective and the toxicity is tolerable


    Original source:

    P opat S, Brustugun OT, Cadranel J, et al .


    P opat S, Brustugun OT, Cadranel J, et al .
    Real-world treatment outcomes with brigatinib in patients with pretreated ALK+ metastatic non-small cell lung cancer.
    Lung Cancer.
    2021 Jul;157:9-16.
    doi: 10.
    1016/j .
    lungcan.
    2021.
    05.
    017.
    Epub 2021 May 24.
    PMID: 34051652.
    P opat S, Brustugun OT, Cadranel J, et al .
    Real-world treatment outcomes with brigatinib in patients with pretreated ALK+ metastatic non-small cell lung cancer.
    Lung Cancer.
    2021 Jul;157:9-16.
    doi: 10.
    1016/j.
    lungcan.
    2021.
    05.
    017.
    Epub 2021 May 24.
    PMID: 34051652.
    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.